Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

References

• Carmona-OrtellsLLoza-SantamaríaEgrupo ESPOGUIAManagement of spondyloarthritis (ESPOGUIA): methodology and general data from the documentReumatol Clin20106Suppl 11521794745
   PubMedGoogle Scholar
• HukudaSMinamiMSaitoTSpondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis SocietyJ Rheumatol20012855455911296958
   PubMed Web of Science ®Google Scholar
• van der HeijdeDLandewéREinsteinSRadiographic progression of ankylosing spondylitis after up to two years of treatment with etanerceptArthritis Rheum2008581324133118438853
   PubMed Web of Science ®Google Scholar
• van der HeijdeDSieperJMaksymowychWPAssessment of SpondyloArthritis international Society2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritisAnn Rheum Dis20117090590821540200
   PubMed Web of Science ®Google Scholar
• GarrettSJenkinsonTKennedyLGWhitelockHGaisfordPCalinAA new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondilytis Disease Activity IndexJ Rheumatol199421228622917699630
   PubMed Web of Science ®Google Scholar
• CalinAGarrettSWhitelockHA new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional IndexJ Rheumatol199421228122857699629
   PubMed Web of Science ®Google Scholar
• JenkinsonTRMalloriePAWhitelockHKennedyLGGarrettSCalinADefining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology IndexJ Rheumatol199421169416987799351
   PubMed Web of Science ®Google Scholar
• AndersonJJBaronGVan der HeijdeDFelsonDTDougadosMAnkylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitisArthritis Rheum2001441876188611508441
   PubMed Web of Science ®Google Scholar
• van der HeijdeDLieEKvienTKASDAS, a highly discriminatory ASAS endorsed disease activity score in patients with ankylosing spondylitisAnn Rheum Dis2009681811181819060001
   PubMed Web of Science ®Google Scholar
• GormanJDSackKEDavisJCJrTreatment of ankylosing spondylitis by inhibition of tumor necrosis factor alphaN Engl J Med20023461349135611986408
   PubMed Web of Science ®Google Scholar
• DavisJCWebbALundSSackKResults from an open-label extension study of etanercept in ankylosing spondylitisArthritis Rheum20045230230415077279
   PubMed Web of Science ®Google Scholar
• BrandtJKhariouzovAListingJSix-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitisArthritis Rheum2003481667167512794835
   PubMed Web of Science ®Google Scholar
• BrandtJListingJHaibelHLong-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitisRheumatology (Oxford)20054434234815561737
   PubMed Web of Science ®Google Scholar
• DavisJCvan der HeijdeDBraunJRecombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis: a randomized controlled trialArthritis Rheum2003483230323614613288
   PubMed Web of Science ®Google Scholar
• DavisJCvan der HeijdeDBraunJEfficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitisAnn Rheum Dis20086734635217967833
   PubMed Web of Science ®Google Scholar
• CalinADijkmansBAEmeryPOutcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitisAnn Rheum Dis200463159460015345498
   PubMed Web of Science ®Google Scholar
• DijkmansBACEmeryPHakalaMEtanercept in the long-term treatment of patients with ankylosing spondylitisJ Rheumatol2009361256126419411393
   PubMed Web of Science ®Google Scholar
• van der HeijdeDDa SilvaJCDougadosMEtanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitisAnn Rheum Dis2006651572157716968715
   PubMed Web of Science ®Google Scholar
• BraunJMcHughNSinghAWajdulaJSSatoRImprovement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weeklyRheumatology (Oxford)200746999100417389658
   PubMed Web of Science ®Google Scholar
• BraunJvan der Horst-BruinsmaIEHuangFClinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trialArthritis Rheum2011631543155121630245
   PubMed Web of Science ®Google Scholar
• LiZHZhangYWangJShiZJEtanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese populationEur J Orthop Surg Traumatol20132349750623412168
   PubMedGoogle Scholar
• McLeodCBagustABolandAAdalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluationHealth Technol Assess2007111158iiiiv
   PubMed Web of Science ®Google Scholar
• Nell-DuxneunerVSchroederYReichardtBBucsicsAThe use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 – a retrospective analysisInt J Clin Pharmacol Ther20125086787223036238
   PubMed Web of Science ®Google Scholar
• GlintborgBOstergaardMKroghNSDreyerLKristensenHLHetlandMLPredictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registryAnn Rheum Dis2010692002200820511613
   PubMed Web of Science ®Google Scholar
• HeibergMSKoldingsnesWMikkelsenKThe comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter studyArthritis Rheum2008155923424018240258
   PubMed Web of Science ®Google Scholar
• PavelkaKForejtováSStolfaJAnti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRAClin Exp Rheumatol20092795896320149312
   PubMed Web of Science ®Google Scholar
• CoatesLCCawkwellLSNgNWReal life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitisRheumatology (Oxford)20084789790018403400
   PubMed Web of Science ®Google Scholar
• ContiFCeccarelliFMarocchiESwitching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year periodAnn Rheum Dis2007661393139717613555
   PubMed Web of Science ®Google Scholar
• DelaunayCFarrenqVMarini-PortugalACohenJDChevalierXClaudepierrePInfliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary dataJ Rheumatol2005322183218516265699
   PubMed Web of Science ®Google Scholar
• RudwaleitMvan der HeijdeDLandewéRThe development of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selectionAnn Rheum Dis2009687783
   Web of Science ®Google Scholar
• HaibelHRudwaleitMListingJEfficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-twoArthritis Rheum2008581981199118576337
   PubMed Web of Science ®Google Scholar
• BarkhamNKeenHICoatesLCClinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitisArthritis Rheum20096094695419333933
   PubMed Web of Science ®Google Scholar
• SongIHHermannKHaibelHEffects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomized controlled trialAnn Rheum Dis20117059059621372193
   PubMed Web of Science ®Google Scholar
• DougadosMvan der HeijdeDSieperJClinical and imaging efficacy of etanercept in early non-radiographic axial spondyloarthritis: a 12-week, randomized, double-blind, placebo-controlled trialAbstract OP0108 presented at the European League Against Rheumatism Annual CongressMadrid, SpainJune 12–15, 2013
   Google Scholar
• DougadosMBraunJSzantoSEfficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)Ann Rheum Dis20117079980421317434
   PubMed Web of Science ®Google Scholar
• DougadosMBraunJSzantoSContinuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE studyRheumatology (Oxford)2012511687169622653382
   PubMed Web of Science ®Google Scholar
• LeonardiCLPowersJLMathesonRTEtanercept Psoriasis Study GroupEtanercept as monotherapy in patients with psoriasisN Engl J Med20033492014202214627786
   PubMed Web of Science ®Google Scholar
• MeasePJGoffeBSMetzJVanderstoepAFinckBBurgeDJEtanercept in the treatment of psoriatic arthritis and psoriasis; a randomised trialLancet200035638539010972371
   PubMed Web of Science ®Google Scholar
• MeasePJKivitzAJBurchFXEtanercept treatment of psoriatic arthritis. Safety, efficacy, and effect on disease progressionArthritis Rheum2004502264227215248226
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBKatzSEtanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trialGastroenterology20011211088109411677200
   PubMed Web of Science ®Google Scholar
• BraunJPavelkaKRamos-RemusCClinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvementJ Rheumatol20123983684022337244
   PubMed Web of Science ®Google Scholar
• WangDMaLWuDEfficacy of etanercept in ankylosing spondylitis hip lesionsJoint Bone Spine20117853153221570332
   PubMed Web of Science ®Google Scholar
• BaraliakosXDavisJTsujiWBraunJMagnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanerceptArthritis Rheum2005521216122315818694
   PubMed Web of Science ®Google Scholar
• RudwaleitMBaraliakosXListingJBrandtJSieperJBraunJMagnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanerceptAnn Rheum Dis2005641305131015778243
   PubMed Web of Science ®Google Scholar
• CreemersMCFranssenMJvan’t HofMAGribnauFWvan de PutteLBvan RielPLAssessment of outcome in ankylosing spondylitis: an extended radiographic scoring systemAnn Rheum Dis20056412712915051621
   PubMed Web of Science ®Google Scholar
• BaraliakosXHaibelHListingJSieperJBraunJContinuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitisAnn Rheum Dis3272013 Epub ahead of print
   Web of Science ®Google Scholar
• van der HeijdeDSalonenDWeissmanBNAssessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 yearsArthritis Res Ther200911R12719703304
   PubMed Web of Science ®Google Scholar
• Navarro-SarabiaFFernández-SueiroJLTorre-AlonsoJCHigh-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)Rheumatology (Oxford)2011501828183721700683
   PubMed Web of Science ®Google Scholar
• LeeSHLeeYAHongSJYangHIEtanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patientsClin Rheumatol20082717918117874173
   PubMed Web of Science ®Google Scholar
• SongIHAlthoffCEHaibelHFrequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trialAnn Rheum Dis2012711212121522440819
   PubMed Web of Science ®Google Scholar
• LeeJNohJWHwangJWExtended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysisClin Rheumatol2010291149115420683738
   PubMed Web of Science ®Google Scholar
• CantiniFNiccoliLCassaràEKaloudiONanniniCDuration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up studyBiologics201371623319853
   PubMedGoogle Scholar
• Navarro-CompánVMoreiraVAriza-ArizaRHernández-CruzBVargas-LebrónCNavarro-SarabiaFLow doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the diseaseClin Rheumatol20113099399621373780
   PubMed Web of Science ®Google Scholar
• CuiYXiaoZShuxiaWComputed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitisScand J Rheumatol200927958963
   Google Scholar
• BarkhamNCoatesLCKeenHDouble-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitisAnn Rheum Dis2010691926192820511615
   PubMed Web of Science ®Google Scholar
• MootsRJOstorAJLoftAGReduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countriesRheumatology (Oxford)20125139339622210658
   PubMed Web of Science ®Google Scholar
• van der BurgLRTer WeeMMBoonenAEffect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic reviewAnn Rheum Dis2012711924193322956595
   PubMed Web of Science ®Google Scholar
• FurstDEWallisRBroderMBeenhouwerDOTumor necrosis factor antagonists: different kinetics and/or mechanisms of acting may explain differences in the risk for developing granulomatous infectionSemin Arthritis Rheum20063615916716884970
   PubMed Web of Science ®Google Scholar
• TraceyDKlareskogLSassoEHSalfeldJGTakPPTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther200811724427918155297
   PubMed Web of Science ®Google Scholar
• MachadoMABarbosaMMAlmeidaAMTreatment of ankylosing spondylitis with TNF blockers: a meta-analysisRheumatol Int5182013 Epub ahead of print
   Web of Science ®Google Scholar
• Martín-MolaESieperJLeirisalo-RepoMSustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ASClin Exp Rheumatol20102823824520483046
   PubMed Web of Science ®Google Scholar
• CarmonaLGómez-ReinoJJBIOBADASER GroupSurvival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASERArthritis Res Ther20068R7216620398
   PubMed Web of Science ®Google Scholar
• Senabre-GallegoJMRosas-Gómez de SalazarJSantos-SolerGDuration of treatment with etanercept and motives for discontinuation in a cohort of patients with rheumatic diseaseReumatol Clin2011738538822078696
   PubMedGoogle Scholar
• DesaiSBFurstDEProblems encountered during anti-tumour necrosis factor therapyBest Pract Res Clin Rheumatol20062075779016979537
   PubMed Web of Science ®Google Scholar
• GrinblatBScheinbergMThe enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a reviewSemin Arthritis Rheum20083725125517640718
   PubMed Web of Science ®Google Scholar
• Santos-RamírezCRosasJSenabreJMEs necesario repetir la prueba de tuberculina en los pacientes en tratamiento biológico? Resultados preliminares en una cohorte local de pacientes con artropatía inflamatoria. [Is it necessary to repeat the tuberculin test in patients on biological treatment? Preliminary results on a local cohort of patients with inflammatory arthropathy.]Rev Sociedad Val Reuma201121516 Spanish
   Google Scholar
• TubachFSalmonDRavaudPRisk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registryArthritis Rheum2009601884189419565495
   PubMed Web of Science ®Google Scholar
• DixonWGHyrichKLWatsonKDLuntMGallowayJUstianowskiADrug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Ann Rheum Dis20106952252819854715
   PubMed Web of Science ®Google Scholar
• AggarwalRManadanAMPoliyedathASequeiraWBlockJASafety of etanercept in patients at high risk for mycobacterial tuberculosis infectionsJ Rheumatol20093691491719332623
   PubMed Web of Science ®Google Scholar
• ZouJRudwaleitMBrandtJThielABraunJSieperJUp regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanerceptAnn Rheum Dis20036256156412759295
   PubMed Web of Science ®Google Scholar
• ZouJRudwaleitMBrandtJThielABraunJSieperJDown-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximabArthritis Rheum20034878079012632433
   PubMed Web of Science ®Google Scholar
• SaintMarcoux BDe BandtMCRI (Club Rhumatismes et Inflammation)Vasculitides induced by TNF alpha antagonists: a study in 39 patients in FranceJoint Bone Spine20067371071317127088
   PubMed Web of Science ®Google Scholar
• Bacquet-DeschryverHJouenFQuillardMImpact of three anti-TNF alpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patientsJ Clin Immunol20082844545518587633
   PubMed Web of Science ®Google Scholar
• BrunassoAMPuntoniMGuliaAMassoneCSafety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic reviewRheumatology (Oxford)2011501700171121690185
   PubMed Web of Science ®Google Scholar
• CepedaEJWilliamsFMIshimoriMLWeismanMHReveilleJDThe use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic diseaseAnn Rheum Dis20086771071218079191
   PubMed Web of Science ®Google Scholar
• LeeESHellerMMKamangarFParkKKKooJYLong-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case studyJ Drugs Dermatol20121141341422395596
   PubMed Web of Science ®Google Scholar
• De VriesMKVan Der Horst-BruinsmaIENurmohamedMImmunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis (AS)Ann Rheum Dis20096853153518375542
   PubMed Web of Science ®Google Scholar
• WolbinkGJAardenLADijkmansBADealing with immunogenicity of biologicals: assessment and clinical relevanceCurr Opin Rheumatol20092121121519399992
   PubMed Web of Science ®Google Scholar
• JamnitskiAKrieckaertCLNurmohamedMTPatients nonresponding to etanercept obtain lower etanercept concentrations compared with responding patientsAnn Rheum Dis201271889121914626
   PubMed Web of Science ®Google Scholar
• DaïenCIDaïenVParussiniEEtanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot studyJ Rheumatol2012391533153822753654
   PubMed Web of Science ®Google Scholar
• DoreRKMathewsSSchechtmanJThe immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritisClin Exp Rheumatol200725404617417989
   PubMed Web of Science ®Google Scholar
• FiorentinoDFThe yin and yang of TNF-alpha inhibitionArch Dermatol200714323323617310003
   PubMedGoogle Scholar
• FurstDEKeystoneECKirkhamBUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2008Ann Rheum Dis200867Suppl 3iii2iii2519022808
   PubMed Web of Science ®Google Scholar
• KrathenMSGottliebABMeasePJPharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritisJ Rheumatol2010372205221520810498
   PubMed Web of Science ®Google Scholar
• Le BlayPMouterdeGBarnetcheTMorelJCombeBRisk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients withrheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studiesClin Exp Rheumatol20123075676422766000
   PubMed Web of Science ®Google Scholar
• LimLLFraunfelderFWRosenbaumJTDo tumor necrosis factor inhibitors cause uveitis? A registry-based studyArthritis Rheum2007563248325217907169
   PubMed Web of Science ®Google Scholar
• JavotLTalaSScala-BertolaJSarcoidosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance system database and literature reviewTherapie201166149154 French21635863
   PubMed Web of Science ®Google Scholar
• PatoEMuñoz-FernándezSFranciscoFSystematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitisSemin Arthritis Rheum20114031432320656330
   PubMed Web of Science ®Google Scholar
• D’AngeloSPalazziCCantiniFLubranoEMarchesoniAMathieuAEtanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issuesClin Exp Rheumatol20112986587022041181
   PubMed Web of Science ®Google Scholar
• MrabetDSelmiAFilaliASahliHSellamiSOnset of Crohn’s disease induced by etanercept therapy: a case reportRev Med Liege201267619622 French23342871
   PubMedGoogle Scholar
• González-LópezMABlancoRGonzález-VelaMCFernández-LlacaHRodríguez-ValverdeVDevelopment of sarcoidosis during etanercept therapyArthritis Rheum20065581782017013853
   PubMed Web of Science ®Google Scholar
• LamrockEBrownPDevelopment of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonistsAustralas J Dermatol201253e87e9023157794
   PubMed Web of Science ®Google Scholar
• FleischmannRIqbalIRisk:benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritisDrugs Aging20072423925417362051
   PubMed Web of Science ®Google Scholar
• SciosciaCSciosciaMAnelliMGPrainoEBettocchiSLapadulaGIntentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritisClin Exp Rheumatol201129939521269575
   PubMed Web of Science ®Google Scholar
• ØstensenMFörgerFManagement of RA medications in pregnant patientsNat Rev Rheumatol2009538239019506586
   PubMed Web of Science ®Google Scholar
• ØstensenMLockshinMDoriaAValesiniGMeroniPGordonCUpdate on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugsRheumatology (Oxford)200847Suppl 3iii28iii3118504282
   PubMed Web of Science ®Google Scholar
• RumpJASchönbornHConception and course of eight pregnancies in five women on TNF blocker etanercept treatmentZ Rheumatol20106990390920532789
   PubMed Web of Science ®Google Scholar
• MahadevanUTerdimanJPAronJJacobsohnSTurekPInfliximab and semen quality in men with inflammatory bowel diseaseInflamm Bowel Dis20051139539915803031
   PubMed Web of Science ®Google Scholar
• SaidTMAgarwalAFalconeTSharmaRKBedaiwyMALiLInfliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro modelFertil Steril2005831665167315950634
   PubMed Web of Science ®Google Scholar
• BorregoLEtanercept in pregnancy and breast-feedingActas Dermosifiliogr2010101Suppl 19710120492888
   PubMedGoogle Scholar